TSE:4528Pharmaceuticals
Could Milestone at PRISM Partnership Reveal Ono Pharmaceutical’s (TSE:4528) Strategy for Oncology Innovation?
PRISM BioLab announced that it has reached an initial milestone in its joint oncology drug discovery collaboration with Ono Pharmaceutical, confirming the receipt of a milestone payment under their agreement first signed in April 2024.
This milestone highlights the advancing application of PRISM's proprietary PepMetics technology, which targets protein-protein interactions to accelerate the development of clinical candidate compounds in cancer treatment.
We'll explore how the achievement of...